0 results for 'Amgen'
Issues Exist if Logistics Firm Is 'Contracting Carrier' Under Montreal Convention
Sidley Crosses $3B in Revenue, With Growing 'Share' of Private Equity Market, Focus on Top Talent
Private equity may have been down in 2023, "but our share of private equity is growing because we've been enlarging that practice," Executive Committee Chair Michael Schmidtberger said.Treatment of Antibody Claims In the U.S. After 'Amgen v. Sanofi'
The future of antibody claiming in the United States is uncertain following the U.S. Supreme Court's ruling in 'Amgen Inc. v. Sanofi,' a highly anticipated decision concerning enablement and whether the traditional way to claim antibodies — claiming antibodies by their function — will survive as a valid claiming strategy.Arnold & Porter Sees Revenue and Profits Jump, With PEP Rising 15% to $1.6M
The environment for counsel on government-facing issues was "quite strong" last year, driving demand across the firm's litigation, transaction and regulatory practices, said chairman Richard Alexander.As Litigation Demand Soared, DC Boutiques Saw Strong Business Year
Several leaders of D.C.-based litigation boutiques said they had strong or solid 2023.View more book results for the query "Amgen"
Pharmaceutical Legal and Regulatory Trends To Watch in 2024
This article highlights several notable legal and regulatory developments in 2023 and discusses developments that will continue to shape the pharmaceutical industry in 2024.Encore! One Last Look at 2023's Litigators of the Week
With one more LOTW set to be named tomorrow, a familiar firm has already clinched the most top spots for the year.The Top Five Patent Decisions of 2023
From life sciences to industrial designs to trade shows, these decisions spanned a wide variety of patent law issues and signal that Constitutional patent rights are still exploring new legal questions and breaking new ground almost 250 years after our nation's founding, says Armond Wilson's Monica Arnold and Michelle Armond.Upping the Dosage: Health Care and Pharmaceuticals Antitrust Regulation in 2023
Antitrust developments in the health care and pharmaceutical industries were exceptionally active in 2023. From the FTC's challenge of a merger between Amgen and Horizon Therapeutics, to joint agency withdrawal of well-established health care merger policy statements, to agency interest in pharmacy benefit managers, the authors review some of the most notable antitrust activity in the health care and pharmaceutical industries over the past year.FTC Struggles to Make Lasting Changes in Antitrust, Former Agency Chairs Say
The agency has signaled its "desire to make a sharp change" through rulemaking but has yet to make lasting alterations through Congress or the courts, said former acting FTC Chair Maureen Ohlhausen.Revenue, Profit, Cash: Managing Law Firms for Success
Brought to you by Juris Ledger
Download Now
Law Firm Operational Considerations for the Corporate Transparency Act
Brought to you by Wolters Kluwer
Download Now
The Ultimate Guide to Remote Legal Work
Brought to you by Filevine
Download Now
Practical Guidance Journal: Protecting Work Product in a Generative AI World
Brought to you by LexisNexis®
Download Now